Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | P4HB | P07237 | 2/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 2/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12181345 | 0.89 | PTGS1 (0.50) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1599758 | 0.79 | CYP3A4 (0.54) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL18626121 | 0.79 | CYP3A4 (0.54) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL7898797 | 0.79 | CYP3A4 (0.54) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL12086931 | 0.79 | SLC6A4 (0.46) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL13226837 | 0.79 | CYP2D6 (0.48) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL13440329 | 0.79 | SLC6A4 (0.46) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL9570585 | 0.78 | CYP3A4 (0.47) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL15165335 | 0.76 | CYP3A4 (0.43) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL13204959 | 0.76 | CYP2D6 (0.46) | CYP3A4MAPK1CYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | RHODIA CHIMIE (FR) | 2003-07-31 | — | — | US | claimed |
| EP-1250303-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2002-10-23 | — | — | EP | claimed |
| WO-2001055067-A1 | METHOD FOR PREPARING ALPHA-HALOGENATED KETONES | RHODIA CHIMIE (FR) | 2001-08-02 | — | — | WO | claimed |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2023-07-13 | — | — | US | disclosed |
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10548891-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2020-02-04 | — | — | US | disclosed |
| EP-2570411-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA HAKKO KIRIN CO LTD (JP) | 2016-07-06 | — | — | EP | disclosed |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA KIRIN CO., LTD. (JP) | 2015-12-10 | — | — | US | disclosed |
| US-9150569-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2015-10-06 | — | — | US | disclosed |
| EP-2570411-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING KYNURENINE PRODUCTION INHIBITORY ACTIVITY | Kyowa Hakko Kirin Co., Ltd. (JP) | 2013-03-20 | — | — | EP | disclosed |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2013-03-14 | — | — | US | disclosed |
| CN-102892759-A | Nitrogen-containing heterocyclic compound having kynurenine production inhibitory action | KYOWA HAKKO KIRIN CO LTD | 2013-01-23 | — | — | CN | disclosed |
| WO-2011142316-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING KYNURENINE PRODUCTION INHIBITORY ACTIVITY | 協和発酵キリン株式会社 (JP) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200179376-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | CYP3A4 707/4885MAPK1 233/4885CYP1A2 1060/4885 |
| US-20150352106-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | CYP3A4 707/4885MAPK1 233/4885CYP1A2 1060/4885 |
| US-10548891-B2 | Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine | KYNU, KMO, IDO1 | CYP3A4 707/4885MAPK1 233/4885CYP1A2 1060/4885 |
| US-20230218612-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | CYP3A4 707/4885MAPK1 233/4885CYP1A2 1060/4885 |
| US-20030144541-A1 | Process for preparing alpha-halogenated retones | ADH1A, ADH1C, RER1 | CYP3A4 492/4885MAPK1 359/4885CYP1A2 177/4885 |
| US-20130065905-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND HAVING INHIBITORY EFFECT ON PRODUCTION OF KYNURENINE | KYNU, KMO, IDO1 | CYP3A4 723/4885MAPK1 223/4885CYP1A2 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.